期刊
LUNG CANCER
卷 65, 期 1, 页码 1-8出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2008.10.018
关键词
Immunotherapy; Cancer vaccine; Adoptive transfer; Cytotoxic T lymphocyte (CTL); Dendritic cell (DC)
资金
- Grants-in-Aid for Scientific Research [21390340] Funding Source: KAKEN
Lung cancer is an intractable disease urgently requiring more effective treatment approaches. The potential of immunotherapy in this context remains promising, although presently there are no satisfactory protocols available for lung cancer. However, encouraging evidence of clinical benefits from immunotherapy is beginning to accumulate in several lung cancer trials. Better understanding of tumor-specific immune responses, identifying tumor-associated antigens, and manipulating the immunoregulatory environment of the tumor is likely to further increase the efficacy of immune-mediated cancer therapies. Here, we review recent advances in cellular immunotherapy and vaccines for lung cancer, emphasizing an important paradigm shift in the analysis of clinical benefit away from tumor response towards patient response. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据